查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041657

紅血球生成素製劑市場預測至2034年－按類型、產品類別、通路、應用、最終用戶和地區分類的全球分析

Erythropoietin Drugs Market Forecasts to 2034 - Global Analysis By Type (Biosimilars and Biologics), Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Products), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 預測，全球促紅血球生成素市場預計到 2026 年將達到 155 億美元，並在預測期內以 13.2% 的複合年成長率成長，到 2034 年達到 418 億美元。

促紅血球生成素製劑是一類含有重組促紅血球生成素的藥物，促紅血球生成素是一種由腎臟自然產生的荷爾蒙。這些藥物旨在刺激和增加紅血球合成，有效緩解貧血相關症狀。透過增加紅血球數，促紅血球生成素製劑可以治療貧血症狀，例如虛弱、呼吸困難和頭暈，從而改善患者的日常生活功能。

根據世界衛生組織（WHO）的數據，全球 42% 的五歲以下兒童和 40% 的孕婦患有貧血。

貧血盛行率增加

貧血是一種以紅血球數量減少或血紅素水平降低為特徵的疾病，導致血液攜氧能力下降。促紅血球生成素（EPO）製劑透過刺激紅血球生成在貧血治療中發揮至關重要的作用。此外，EPO製劑也常用於治療化療引起的貧血，並改善癌症患者的生活品質。這些疾病盛行率的不斷上升加重了貧血對整體人群的負擔，從而推高了對EPO製劑的需求。

潛在副作用

促紅血球生成素市場面臨與治療用途相關的副作用的潛在限制因素。其中一個主要擔憂是促紅血球生成素給藥可能引發血栓症和高血壓等心血管事件的風險。另一個潛在的副作用是純紅血球生成相關性紅血球生成症（PRCA）的發生，這是一種罕見但嚴重的疾病，其特徵是紅血球生成突然停止。

人們對醫療保健的認知不斷提高

醫療保健意識的不斷提高是紅血球生成素市場的主要驅動力。隨著患者和醫療專業人員對包括貧血在內的各種健康狀況的認知不斷增強，紅血球生成素在治療貧血相關併發症的重要性也日益凸顯。此外，患者越來越希望獲得針對慢性腎臟病和其他需要紅血球生成素發揮關鍵作用的疾病的及時有效的治療方法。這些因素共同推動了市場需求。

新型替代療法的興起

隨著科學和醫學研究的進步，包括非藥物療法和替代療法在內的新治療方案日益受到關注，對促紅血球生成素製劑的市場主導地位構成了挑戰。此外，生物相似藥在市場上的普及和應用日益廣泛，可能導致價格壓力和市場競爭加劇，進而影響品牌促紅血球生成素製劑的收入。

新冠疫情的感染疾病

新冠疫情對促紅血球生成素市場造成了顯著衝擊。包括用於治療貧血的促紅血球生成素製劑在內的非緊急醫療程序和治療被推遲或延期，影響了整體市場需求。此外，藥品供應鏈中斷、旅行限制和勞動力短缺也阻礙了促紅血球生成素製劑的生產和分銷。

在預測期內，腫瘤領域預計將佔據最大佔有率。

據估計，癌症患者佔比最大。癌症患者常因疾病本身和化療的副作用而出現貧血。促紅血球生成素製劑，例如重組人類促紅血球生成素（epoetin alfa），透過刺激紅血球生成來治療癌症患者的貧血。此外，促紅血球生成素療法可透過維持足夠的攜氧紅血球水平來改善患者的整體健康狀況，並使癌症治療更加有效。

在預測期內，生物製劑領域預計將呈現最高的複合年成長率。

預計生物製劑部門在預測期內將顯著成長。生物製劑產品旨在模擬促紅血球生成素的天然功能，促紅血球生成素刺激骨髓中紅血球的生成。促紅血球生成素製劑廣泛用於治療慢性腎臟病、癌症化療及其他特定疾病所引起的貧血。此外，包括促紅血球生成素製劑在內的生物製藥產品，透過提供針對性強、療效顯著的貧血治療方案，為患者照護做出了重要貢獻。

市佔率最大的地區：

由於北美擁有完善的醫療保健基礎設施、技術創新以及較高的疾病盛行率，因此在預測期內佔據了最大的市場佔有率。貧血的盛行率，尤其是在接受透析治療的慢性腎臟病（CKD）患者和接受癌症治療的患者中，推動了北美對促紅血球生成素製劑的需求。此外，該地區在生物技術和藥物研究方面處於領先地位，並持續推動促紅血球生成素製劑的研發創新。

複合年成長率最高的地區：

由於亞太地區對全球製藥業的重大貢獻，預計該地區在預測期內將實現盈利成長。中國和印度等國家正在崛起，成為促紅血球生成素製劑生產和消費的主要參與者。該地區的製藥業受益於積極的研發活動，這些活動推動了創新和新型促紅血球生成素製劑的推出。此外，亞太地區醫療基礎設施的完善和醫療支出的成長也促進了促紅血球生成素製劑市場的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球促紅血球生成素市場：按類型分類

  • 生物相似藥
  • 生物製劑

第6章 全球促紅血球生成素市場：依產品分類

  • 促紅素α
  • 促紅血球生成素BETA
  • Darbepoetinα
  • 其他產品

第7章 全球促紅血球生成素市場：依分銷管道分類

  • 網路藥房
  • 醫院藥房
  • 其他分銷管道

第8章 全球促紅血球生成素市場：依應用分類

  • 血液學
  • 癌症
  • 神經病學
  • 腎臟疾病
  • 其他用途

第9章 全球促紅血球生成素市場：依最終用戶分類

  • 專科診所
  • 醫院
  • 其他最終用戶

第10章 全球促紅血球生成素市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • Amgen, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc
  • LG Chem
  • F. Hoffmann-La Roche Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories Ltd
  • Ranbaxy Laboratories
  • Roche Diagnostics
Product Code: SMRC25051

According to Stratistics MRC, the Global Erythropoietin Drugs Market is accounted for $15.5 billion in 2026 and is expected to reach $41.8 billion by 2034 growing at a CAGR of 13.2% during the forecast period. Erythropoietin drugs are a class of medications that include recombinant forms of erythropoietin, a hormone produced naturally in the kidneys. These drugs are designed to stimulate and increase the synthesis of red blood cells, making them effective in managing conditions associated with anaemia. Erythropoietin medications treat anaemia symptoms such as weakness, dyspnea, and vertigo by raising red blood cell counts, leading to improved daily functioning for patients.

According to the World Health Organization (WHO), 42% of children under the age of five and 40% of pregnant women worldwide are anemic.

Market Dynamics:

Driver:

Rising prevalence of anaemia

Anaemia is a condition characterized by a decrease in the number of red blood cells or a decrease in the amount of haemoglobin, leading to reduced oxygen-carrying capacity in the blood. EPO drugs play a crucial role in managing anaemia by stimulating the production of red blood cells. Moreover, EPO drugs are often prescribed to cancer patients to manage chemotherapy-induced anaemia and improve their quality of life. The increasing prevalence of these conditions contributes to the overall burden of anaemia in the population, thereby driving the demand for EPO drugs.

Restraint:

Potential adverse effects

The erythropoietin drug market faces potential restraints linked to the occurrence of adverse effects associated with the therapeutic use of these drugs. One significant concern is the risk of cardiovascular events, including thrombosis and hypertension, associated with the administration of erythropoietin drugs. Furthermore, another potential adverse effect is the development of pure red cell aplasia (PRCA), a rare but serious condition characterized by a sudden halt in the production of red blood cells.

Opportunity:

Increased healthcare awareness

Increased healthcare awareness serves as a pivotal driver in the erythropoietin drugs market. As awareness about health conditions, including anemia, continues to rise among patients and healthcare professionals, there is a heightened recognition of the significance of erythropoietin drugs in managing anemia-associated complications. Moreover, patients are increasingly seeking timely and effective treatments for conditions like chronic kidney disease and other disorders where erythropoietin drugs play a vital role. These factors drive market demand.

Threat:

Emerging alternatives

As scientific and medical research progresses, new therapeutic options, including non-pharmacological interventions and alternative drug therapies, are gaining attention and posing a challenge to the dominance of erythropoietin drugs. Moreover, the increasing availability and adoption of biosimilars in the market can lead to pricing pressures and market share competition, impacting the revenue of branded erythropoietin drugs.

Covid-19 Impact

The erythropoietin drug market experienced notable impacts from the COVID-19 pandemic. Non-urgent medical procedures and treatments, including those involving erythropoietin drugs for anaemia, were deferred or delayed, affecting the overall market demand. Additionally, disruptions in the pharmaceutical supply chain, restrictions on movement, and workforce shortages posed obstacles to the production and distribution of erythropoietin drugs.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to hold the largest share. Cancer patients frequently experience anaemia due to the effects of the disease itself or as a side effect of chemotherapy. Erythropoietin drugs, such as epoetin-alfa, are employed to address anaemia in cancer patients by stimulating the production of red blood cells. Moreover, erythropoietin therapies improve the patient's well-being, potentially allowing for more effective cancer treatment by maintaining adequate levels of oxygen-carrying red blood cells.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment is anticipated to have lucrative growth during the forecast period. Biologics are designed to mimic the natural function of erythropoietin in stimulating the production of red blood cells in the bone marrow. Erythropoietin biologics are commonly used to address anaemia associated with chronic kidney disease, cancer chemotherapy, and certain other medical conditions. Additionally, biologics, including erythropoietin-based agents, contribute significantly to patient care by offering targeted and effective treatments for anaemia.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, technological innovation, and a high prevalence of conditions. The prevalence of anaemia, particularly in CKD patients undergoing dialysis and individuals undergoing cancer treatments, has fuelled the demand for erythropoietin drugs in North America. Moreover, the region is also at the forefront of biotechnological and pharmaceutical research, driving continuous innovation in erythropoietin drug development.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, owing to its significant contribution to the global pharmaceutical industry. Countries like China and India have emerged as key players in the production and consumption of erythropoietin drugs. The region's pharmaceutical sector benefits from robust research and development activities, fostering innovation and the introduction of new EPO formulations. Additionally, the Asia-Pacific's evolving healthcare infrastructure and increasing healthcare expenditure contribute to the growth of the erythropoietin drug market.

Key players in the market

Some of the key players in the Erythropoietin Drugs Market include Johnson & Johnson Services, Inc., AstraZeneca, Amgen, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc, LG Chem, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd, Ranbaxy Laboratories and Roche Diagnostics.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In September 2023, Sun Pharmaceutical Industries Limited announced that it had entered into a licence agreement with American biopharmaceutical company Pharmazz Inc to commercialise an innovative drug, Tyvalzi (Sovateltide) in India.

In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

In October 2020, Novartis and Molecular Partners AG announced collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin(R) program, consisting of two therapeutic candidates, MP0420 and MP0423.

Types Covered:

  • Biosimilars
  • Biologics

Products Covered:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Other Products

Distribution Channels Covered:

  • Online Pharmacy
  • Hospital Pharmacy
  • Other Distribution Channels

Applications Covered:

  • Hematology
  • Cancer
  • Neurology
  • Renal Diseases
  • Other Applications

End Users Covered:

  • Speciality Clinics
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Erythropoietin Drugs Market, By Type

  • 5.1 Introduction
  • 5.2 Biosimilars
  • 5.3 Biologics

6 Global Erythropoietin Drugs Market, By Product

  • 6.1 Introduction
  • 6.2 Epoetin-alfa
  • 6.3 Epoetin-beta
  • 6.4 Darbepoetin-alfa
  • 6.5 Other Products

7 Global Erythropoietin Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Online Pharmacy
  • 7.3 Hospital Pharmacy
  • 7.4 Other Distribution Channels

8 Global Erythropoietin Drugs Market, By Application

  • 8.1 Introduction
  • 8.2 Hematology
  • 8.3 Cancer
  • 8.4 Neurology
  • 8.5 Renal Diseases
  • 8.6 Other Applications

9 Global Erythropoietin Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Speciality Clinics
  • 9.3 Hospitals
  • 9.4 Other End Users

10 Global Erythropoietin Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Johnson & Johnson Services, Inc.
  • 12.2 AstraZeneca
  • 12.3 Amgen, Inc.
  • 12.4 Novartis AG
  • 12.5 Teva Pharmaceutical Industries Ltd.
  • 12.6 Pfizer Inc
  • 12.7 LG Chem
  • 12.8 F. Hoffmann-La Roche Ltd.
  • 12.9 Sun Pharmaceutical Industries Ltd.
  • 12.10 Intas Pharmaceuticals Ltd.
  • 12.11 Dr. Reddy's Laboratories Ltd
  • 12.12 Ranbaxy Laboratories
  • 12.13 Roche Diagnostics

List of Tables

  • Table 1 Global Erythropoietin Drugs Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Erythropoietin Drugs Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Erythropoietin Drugs Market Outlook, By Biosimilars (2023-2034) ($MN)
  • Table 4 Global Erythropoietin Drugs Market Outlook, By Biologics (2023-2034) ($MN)
  • Table 5 Global Erythropoietin Drugs Market Outlook, By Product (2023-2034) ($MN)
  • Table 6 Global Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2023-2034) ($MN)
  • Table 7 Global Erythropoietin Drugs Market Outlook, By Epoetin-beta (2023-2034) ($MN)
  • Table 8 Global Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2023-2034) ($MN)
  • Table 9 Global Erythropoietin Drugs Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 10 Global Erythropoietin Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 11 Global Erythropoietin Drugs Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 12 Global Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 13 Global Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 14 Global Erythropoietin Drugs Market Outlook, By Application (2023-2034) ($MN)
  • Table 15 Global Erythropoietin Drugs Market Outlook, By Hematology (2023-2034) ($MN)
  • Table 16 Global Erythropoietin Drugs Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 17 Global Erythropoietin Drugs Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 18 Global Erythropoietin Drugs Market Outlook, By Renal Diseases (2023-2034) ($MN)
  • Table 19 Global Erythropoietin Drugs Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 20 Global Erythropoietin Drugs Market Outlook, By End User (2023-2034) ($MN)
  • Table 21 Global Erythropoietin Drugs Market Outlook, By Speciality Clinics (2023-2034) ($MN)
  • Table 22 Global Erythropoietin Drugs Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 23 Global Erythropoietin Drugs Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 24 North America Erythropoietin Drugs Market Outlook, By Country (2023-2034) ($MN)
  • Table 25 North America Erythropoietin Drugs Market Outlook, By Type (2023-2034) ($MN)
  • Table 26 North America Erythropoietin Drugs Market Outlook, By Biosimilars (2023-2034) ($MN)
  • Table 27 North America Erythropoietin Drugs Market Outlook, By Biologics (2023-2034) ($MN)
  • Table 28 North America Erythropoietin Drugs Market Outlook, By Product (2023-2034) ($MN)
  • Table 29 North America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2023-2034) ($MN)
  • Table 30 North America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2023-2034) ($MN)
  • Table 31 North America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2023-2034) ($MN)
  • Table 32 North America Erythropoietin Drugs Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 33 North America Erythropoietin Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 34 North America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 35 North America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 36 North America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 37 North America Erythropoietin Drugs Market Outlook, By Application (2023-2034) ($MN)
  • Table 38 North America Erythropoietin Drugs Market Outlook, By Hematology (2023-2034) ($MN)
  • Table 39 North America Erythropoietin Drugs Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 40 North America Erythropoietin Drugs Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 41 North America Erythropoietin Drugs Market Outlook, By Renal Diseases (2023-2034) ($MN)
  • Table 42 North America Erythropoietin Drugs Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 43 North America Erythropoietin Drugs Market Outlook, By End User (2023-2034) ($MN)
  • Table 44 North America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2023-2034) ($MN)
  • Table 45 North America Erythropoietin Drugs Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 46 North America Erythropoietin Drugs Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 47 Europe Erythropoietin Drugs Market Outlook, By Country (2023-2034) ($MN)
  • Table 48 Europe Erythropoietin Drugs Market Outlook, By Type (2023-2034) ($MN)
  • Table 49 Europe Erythropoietin Drugs Market Outlook, By Biosimilars (2023-2034) ($MN)
  • Table 50 Europe Erythropoietin Drugs Market Outlook, By Biologics (2023-2034) ($MN)
  • Table 51 Europe Erythropoietin Drugs Market Outlook, By Product (2023-2034) ($MN)
  • Table 52 Europe Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2023-2034) ($MN)
  • Table 53 Europe Erythropoietin Drugs Market Outlook, By Epoetin-beta (2023-2034) ($MN)
  • Table 54 Europe Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2023-2034) ($MN)
  • Table 55 Europe Erythropoietin Drugs Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 56 Europe Erythropoietin Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 57 Europe Erythropoietin Drugs Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 58 Europe Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 59 Europe Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 60 Europe Erythropoietin Drugs Market Outlook, By Application (2023-2034) ($MN)
  • Table 61 Europe Erythropoietin Drugs Market Outlook, By Hematology (2023-2034) ($MN)
  • Table 62 Europe Erythropoietin Drugs Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 63 Europe Erythropoietin Drugs Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 64 Europe Erythropoietin Drugs Market Outlook, By Renal Diseases (2023-2034) ($MN)
  • Table 65 Europe Erythropoietin Drugs Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 66 Europe Erythropoietin Drugs Market Outlook, By End User (2023-2034) ($MN)
  • Table 67 Europe Erythropoietin Drugs Market Outlook, By Speciality Clinics (2023-2034) ($MN)
  • Table 68 Europe Erythropoietin Drugs Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 69 Europe Erythropoietin Drugs Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 70 Asia Pacific Erythropoietin Drugs Market Outlook, By Country (2023-2034) ($MN)
  • Table 71 Asia Pacific Erythropoietin Drugs Market Outlook, By Type (2023-2034) ($MN)
  • Table 72 Asia Pacific Erythropoietin Drugs Market Outlook, By Biosimilars (2023-2034) ($MN)
  • Table 73 Asia Pacific Erythropoietin Drugs Market Outlook, By Biologics (2023-2034) ($MN)
  • Table 74 Asia Pacific Erythropoietin Drugs Market Outlook, By Product (2023-2034) ($MN)
  • Table 75 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2023-2034) ($MN)
  • Table 76 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-beta (2023-2034) ($MN)
  • Table 77 Asia Pacific Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2023-2034) ($MN)
  • Table 78 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 79 Asia Pacific Erythropoietin Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 80 Asia Pacific Erythropoietin Drugs Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 81 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 82 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 83 Asia Pacific Erythropoietin Drugs Market Outlook, By Application (2023-2034) ($MN)
  • Table 84 Asia Pacific Erythropoietin Drugs Market Outlook, By Hematology (2023-2034) ($MN)
  • Table 85 Asia Pacific Erythropoietin Drugs Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 86 Asia Pacific Erythropoietin Drugs Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 87 Asia Pacific Erythropoietin Drugs Market Outlook, By Renal Diseases (2023-2034) ($MN)
  • Table 88 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 89 Asia Pacific Erythropoietin Drugs Market Outlook, By End User (2023-2034) ($MN)
  • Table 90 Asia Pacific Erythropoietin Drugs Market Outlook, By Speciality Clinics (2023-2034) ($MN)
  • Table 91 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 92 Asia Pacific Erythropoietin Drugs Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 93 South America Erythropoietin Drugs Market Outlook, By Country (2023-2034) ($MN)
  • Table 94 South America Erythropoietin Drugs Market Outlook, By Type (2023-2034) ($MN)
  • Table 95 South America Erythropoietin Drugs Market Outlook, By Biosimilars (2023-2034) ($MN)
  • Table 96 South America Erythropoietin Drugs Market Outlook, By Biologics (2023-2034) ($MN)
  • Table 97 South America Erythropoietin Drugs Market Outlook, By Product (2023-2034) ($MN)
  • Table 98 South America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2023-2034) ($MN)
  • Table 99 South America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2023-2034) ($MN)
  • Table 100 South America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2023-2034) ($MN)
  • Table 101 South America Erythropoietin Drugs Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 102 South America Erythropoietin Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 103 South America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 104 South America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 105 South America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 106 South America Erythropoietin Drugs Market Outlook, By Application (2023-2034) ($MN)
  • Table 107 South America Erythropoietin Drugs Market Outlook, By Hematology (2023-2034) ($MN)
  • Table 108 South America Erythropoietin Drugs Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 109 South America Erythropoietin Drugs Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 110 South America Erythropoietin Drugs Market Outlook, By Renal Diseases (2023-2034) ($MN)
  • Table 111 South America Erythropoietin Drugs Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 112 South America Erythropoietin Drugs Market Outlook, By End User (2023-2034) ($MN)
  • Table 113 South America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2023-2034) ($MN)
  • Table 114 South America Erythropoietin Drugs Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 115 South America Erythropoietin Drugs Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 116 Middle East & Africa Erythropoietin Drugs Market Outlook, By Country (2023-2034) ($MN)
  • Table 117 Middle East & Africa Erythropoietin Drugs Market Outlook, By Type (2023-2034) ($MN)
  • Table 118 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biosimilars (2023-2034) ($MN)
  • Table 119 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biologics (2023-2034) ($MN)
  • Table 120 Middle East & Africa Erythropoietin Drugs Market Outlook, By Product (2023-2034) ($MN)
  • Table 121 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2023-2034) ($MN)
  • Table 122 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-beta (2023-2034) ($MN)
  • Table 123 Middle East & Africa Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2023-2034) ($MN)
  • Table 124 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 125 Middle East & Africa Erythropoietin Drugs Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 126 Middle East & Africa Erythropoietin Drugs Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 127 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 128 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2023-2034) ($MN)
  • Table 129 Middle East & Africa Erythropoietin Drugs Market Outlook, By Application (2023-2034) ($MN)
  • Table 130 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hematology (2023-2034) ($MN)
  • Table 131 Middle East & Africa Erythropoietin Drugs Market Outlook, By Cancer (2023-2034) ($MN)
  • Table 132 Middle East & Africa Erythropoietin Drugs Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 133 Middle East & Africa Erythropoietin Drugs Market Outlook, By Renal Diseases (2023-2034) ($MN)
  • Table 134 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 135 Middle East & Africa Erythropoietin Drugs Market Outlook, By End User (2023-2034) ($MN)
  • Table 136 Middle East & Africa Erythropoietin Drugs Market Outlook, By Speciality Clinics (2023-2034) ($MN)
  • Table 137 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 138 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other End Users (2023-2034) ($MN)